In yesterday’s Wall Street session, DexCom Inc. (NASDAQ:DXCM) shares traded at $107.81, down -3.01% from the previous session.
As of this writing, 23 analysts cover DexCom Inc. (NASDAQ:DXCM). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $175.00 and a low of $131.00, we find $150.00. Given the previous closing price of $111.16, this indicates a potential upside of 34.94 percent. DXCM stock price is now -14.32% away from the 50-day moving average and -8.34% away from the 200-day moving average. The market capitalization of the company currently stands at $42.41B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
There are 2 analysts who have given it a hold rating, whereas 17 have given it a buy rating. Brokers who have rated the stock have averaged $150.88 as their price target over the next twelve months.
In other news, Stern Sadie, EVP Chief Human Resources Offi sold 392 shares of the company’s stock on Aug 09. The stock was sold for $43,398 at an average price of $110.71. Upon completion of the transaction, the EVP Chief Human Resources Offi now directly owns 81,682 shares in the company, valued at $8.81 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 24, EVP Managing Director Dexcom V Pacelli Steven Robert sold 412 shares of the business’s stock. A total of $53,799 was realized by selling the stock at an average price of $130.58. This leaves the insider owning 126,419 shares of the company worth $13.63 million. Insiders disposed of 467,688 shares of company stock worth roughly $50.42 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DXCM stock. A new stake in DexCom Inc. shares was purchased by UNISUPER MANAGEMENT PTY LTD during the first quarter worth $17,982,000. CANTOR FITZGERALD, L. P. invested $17,357,000 in shares of DXCM during the first quarter. In the first quarter, BLACKSTONE INC. acquired a new stake in DexCom Inc. valued at approximately $17,250,000. COVEA FINANCE acquired a new stake in DXCM for approximately $16,484,000. HBK INVESTMENTS L P purchased a new stake in DXCM valued at around $6,476,000 in the second quarter.
Thursday morning saw DexCom Inc. (NASDAQ: DXCM) opened at $111.10. During the past 12 months, DexCom Inc. has had a low of $78.94 and a high of $139.55. As of last week, the company has a debt-to-equity ratio of 1.55, a current ratio of 2.40, and a quick ratio of 2.20. According to the stock market information, the enterprise value for the company is $42.85B, which is based on a 128.65 price-to-earnings ratio, a 3.51 price-to-earnings-growth ratio, and a beta of 1.11. The fifty day moving average price for DXCM is $125.48 and a two-hundred day moving average price translates $117.56 for the stock.
The latest earnings results from DexCom Inc. (NASDAQ: DXCM) was released for Jun, 2023. According to the Medical Devices Company, earnings per share came in at $0.34, beating analysts’ expectations of $0.23 by 0.11. This compares to $0.12 EPS in the same period last year. The net profit margin was 11.20% and return on equity was 17.30% for DXCM. The company reported revenue of $871.3 million for the quarter, compared to $696.2 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 25.15 percent. For the current quarter, analysts expect DXCM to generate $939.31M in revenue.
